Abstract
The extrapyramidal side effect parameters of typical and atypical antypsychotics were correlated with affinity chromatographic data determined on the melanin-based column. The chromatographic study was performed according to the hypothesis that extrapyramidal symptoms (EPS) as side effects of the use of antipsychotic drugs at clinically effective doses are correlated to the affinity of these drugs to neuromelanin. For that aim the polymerization product of L-DOPA (melanin) was immobilized onto aminopropyl silica and the binding efficiency of melanin towards antipsychotics has been determined. The results indicate that melanin based-column can be used to evaluate the risk of EPS of drug candidates to antipsychotic drug therapy.
Keywords: Affinity chromatography, antipsychotics, drug-binding, extrapyramidal symptoms, melanin binding
Current Pharmaceutical Analysis
Title:Affinity Chromatography Method for Determination of Binding of Drugs to Melanin and Evaluation of Side Effect Potential of Antipsychotic Agents
Volume: 9 Issue: 2
Author(s): Michal Piotr Marszall, Anna Proszowska, Adam Bucinski and Roman Kaliszan
Affiliation:
Keywords: Affinity chromatography, antipsychotics, drug-binding, extrapyramidal symptoms, melanin binding
Abstract: The extrapyramidal side effect parameters of typical and atypical antypsychotics were correlated with affinity chromatographic data determined on the melanin-based column. The chromatographic study was performed according to the hypothesis that extrapyramidal symptoms (EPS) as side effects of the use of antipsychotic drugs at clinically effective doses are correlated to the affinity of these drugs to neuromelanin. For that aim the polymerization product of L-DOPA (melanin) was immobilized onto aminopropyl silica and the binding efficiency of melanin towards antipsychotics has been determined. The results indicate that melanin based-column can be used to evaluate the risk of EPS of drug candidates to antipsychotic drug therapy.
Export Options
About this article
Cite this article as:
Piotr Marszall Michal, Proszowska Anna, Bucinski Adam and Kaliszan Roman, Affinity Chromatography Method for Determination of Binding of Drugs to Melanin and Evaluation of Side Effect Potential of Antipsychotic Agents, Current Pharmaceutical Analysis 2013; 9 (2) . https://dx.doi.org/10.2174/1573412911309020002
DOI https://dx.doi.org/10.2174/1573412911309020002 |
Print ISSN 1573-4129 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-676X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inflammatory Mediators in Epilepsy
Current Pharmaceutical Design Congenital Abnormalities: Consequence of Maternal Zika Virus Infection: A Narrative Review
Infectious Disorders - Drug Targets The Effects of Psychopharmacologic and Therapeutic Approaches on Neuro-imaging in Obsessive-compulsive Disorder
Current Neuropharmacology Characterization of Bacteriological Isolates from Patients and Environment Samples of Burn Ward: A Study from a Tertiary Care Hospital of India
Infectious Disorders - Drug Targets Multidrug Resistance: Retrospect and Prospects in Anti-Cancer Drug Treatment
Current Medicinal Chemistry Current Knowledge on Low Back Pain and Pelvic Girdle Pain During Pregnancy and after Childbirth: A Narrative Review
Current Women`s Health Reviews Vasoactive Intestinal Peptide in Neurodevelopmental Disorders:Therapeutic Potential
Current Pharmaceutical Design Possible Physiopathological Roles of the Transglutaminase Activity in the Etiopathogenesis of Human Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Amyloid Beta 1-42 Inhibits Entorhinal Cortex Activity in the Beta-Gamma Range: Role of GSK-3
Current Alzheimer Research Anti-NMDA Receptor Encephalitis, Vaccination and Virus
Current Pharmaceutical Design AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models
Current Alzheimer Research <i>Drosophila melanogaster</i> a Versatile Model of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Cognitive Flexibility as a Key Factor in the Conceptualization and Treatment of PTSD
Current Psychiatry Reviews Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology Fluorogold Induces Persistent Neurological Deficits and Circling Behavior in Mice Over-Expressing Human Mutant Tau
Current Neurovascular Research Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson’s Disease
Current Pharmaceutical Design TMS - A New Neuroimaging Combinational Tool to Study Brain Function
Current Medical Imaging Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases
Current Medicinal Chemistry Recent Progress and Patents in Silicon Nanotubes
Recent Patents on Nanotechnology Age-Related Inflammation: the Contribution of Different Organs, Tissues and Systems. How to Face it for Therapeutic Approaches
Current Pharmaceutical Design